Multicenter hemodynamic assessment of the LOT-CRT strategy: When is one lead enough for resynchronization?



Primary results of the CSPOT-study

Marek Jastrzębski¹, Paul Foley, Badrinathan Chandrasekaran, Zachary Whinnett, Pugazhendhi Vijayaraman, Gaurav A Upadhyay, Robert D. Schaller, Rafał Gardas, Travis Richardson, D'Anne Kudlik, Robert W. Stadler, Patrick Zimmerman, James Burrell, Robert Waxman, Richard N Cornelussen, Jonathan Lyne and Bengt Herweg.

¹First Department of Cardiology, Interventional Electrocardiology and Hypertension, Jagiellonian University, Medical College, Krakow, Poland.

7th April 2024,



Declaration of Interest

- I have nothing to declare



Left bundle branch-optimized cardiac resynchronization therapy (LOT-CRT): Results from an international LBBAP collaborative study group

Marek Jastrzębski, MD, PhD,* Paweł Moskal, MD, PhD,* Wim Huybrechts, MD,[†] Karol Curila, MD, PhD,[‡] Praveen Sreekumar, MBBS, MD, DM,[§] Leonard M. Rademakers, MD, PhD,^{||} Shunmuga Sundaram Ponnusamy, MBBS, MD, CEPS-A,[¶] Bengt Herweg, MD, FHRS,[#] Parikshit S. Sharma, MD, MPH, FACC, FHRS,** Agnieszka Bednarek, MD, PhD,* Marek Rajzer, MD, PhD,* Pugazhendhi Vijayaraman, MD, FHRS^{††}

Background

In patients undergoing cardiac resynchronization therapy using left bundle branch area pacing (LBBAP), the addition of a coronary venous lead (Left bundle branch optimized CRT [LOT-CRT]) might confer additional benefits.

Which patients benefit from the

LOT-CRT pacing strategy?

Objective

To compare the acute hemodynamic and electrocardiographic characteristics between conventional Biventricular Pacing (BVP), LBBAP and LOT-CRT



CV LV



Study design and patient characteristics

The Conduction System Pacing Optimized Therapy (CSPOT) study, ClinicalTrials.gov NCT04905290, was a prospective, multicenter (5 EU and 7 US centres), study of LBBAP in CRT-indicated subjects.





Acute experimental pacing and acquisition set-up.

Characteristic	Mean (95% Cl) or Frequency (Percent)
Male sex	32 (67%)
BMI	30.0 (28.6-31.3)
Ischemic cardiomyopathy	14 (29%)
ECG	
PR interval (ms)	202 (186, 217)
Blood pressure (mmHg)	
Systolic	120.7 (115.3-, 126.1)
Diastolic	70.2 (66.9-, 73.4)
NYHA classification	
1	3 (6%)
11	26 (54%)
III	16 (33%)
IV	1 (2%)
Conduction disease	
LBBB	19 (40%)
IVCD	27 (60%)
Echocardiography	
LVEF (%)	29.8 (25.9-33.7)
LVESV (ml)	143.4 (124.1-162.6)
LVEDV (ml)	201.5 (179.6-223.3)

Procedural Characteristic	Mean (95% Cl) or Frequency (Percent)
QRS duration (ms)	171 (165-177)
PR interval (atrial paced) (ms)	248 (229-267)
Q-LV interval (ms)	130 (120-140)
Q-LV/QRS duration (%)	75 (71-85)
Baseline (AAI) LV dP/dt (mmHg/sec)	846 (779-914)
Successful LBBAP	27 (56%)
DSP	21 (44%)
Anodal stimulation during LBBAP	25 (54%)

Improved LV dP/dt_{max} and QRS-duration shortening with LOT-CRT



Displayed are means \pm 95% confidence intervals. * indicates P≤0.005.

EHRA

Importance of Baseline QRS-duration in acute response



LV dP/dt_{max}

QRS-duration shortening



EHRA/2024 -----

Conclusions

EHRA/2024

In a CRT cohort with advanced/difficult ventricular conduction system disease, LOT-CRT and BVP provided greater acute hemodynamic benefit than LBBAP alone.



Subjects with wider QRS or suboptimal outcome of LBBAP (i.e., DSP) are more likely to benefit from addition of a LVcv lead to implement LOT-CRT.





The SUBSTRATE

The CAPTURE type

Limitations

- No firm LBB capture confirmation
- Small study size
- Predominantly NIVCD patients
- Not representative of general CRT population
- Focuse on acute responses